Abstract
N6-methyladenosine (m(6)A) modification, as the most common modification method in eukaryotes, is widely involved in numerous physiological and pathological processes, such as embryonic development, malignancy, immune regulation, and premature aging. Under pathological conditions of ocular diseases, changes in m(6)A modification and its metabolism can be detected in aqueous and vitreous humor. At the same time, an increasing number of studies showed that m(6)A modification is involved in the normal development of eye structures and the occurrence and progress of many ophthalmic diseases, especially ocular neovascular diseases, such as diabetic retinopathy, age-related macular degeneration, and melanoma. In this review, we summarized the latest progress regarding m(6)A modification in ophthalmic diseases, changes in m(6)A modification-related enzymes in various pathological states and their upstream and downstream regulatory networks, provided new prospects for m(6)A modification in ophthalmic diseases and new ideas for clinical diagnosis and treatment.